Welcome to our dedicated page for BioLife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on BioLife Solutions stock.
BioLife Solutions develops and supplies cell processing tools and bioproduction products for the cell and gene therapy market and broader biopharma customers. Company news commonly covers financial results from continuing operations, demand for biopreservation media, and the role of its products in maintaining biologic material during collection, development, manufacturing, storage, distribution, and thawing.
Recurring updates also include product-portfolio expansion, supply agreements for cell and gene therapy manufacturing inputs, CellSeal vial systems, human platelet lysate products, cytokine and growth factor distribution, and research activity tied to biopreservation and cryopreservation technologies.
BioLife Solutions (NASDAQ: BLFS) announced a proposed public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered. The offering is subject to market conditions and there's no guarantee of completion. Proceeds will be used for general corporate purposes, including potential investments or acquisitions that complement BioLife's technology. Cowen, Oppenheimer & Co., and Stephens Inc. will manage the offering. All shares will be offered under an effective shelf registration statement filed with the SEC.